Key result
Enoxaparin treatment was associated with a significantly longer mean survival time (7.6 months) compared to tinzaparin (2.8 months) in cancer patients with venous thromboembolism.
Why the study?
Venous thromboembolism is associated with increased morbidity and mortality in cancer patients and represents one of their most frequent causes of death.
Does enoxaparin compared to tinzaparin improve survival and resolve VTE in cancer patients?
Cohort (n=36)
No
Does enoxaparin compared to tinzaparin improve survival and resolve VTE in cancer patients?
Absolute Event Rate: 7.6% vs 2.8%
p-value: p=<0.05
In a small cohort of cancer patients with VTE, enoxaparin was associated with a longer survival time compared to tinzaparin, while both LMWHs effectively resolved thrombosis without bleeding complications.
May support enoxaparin preference in cancer VTE; hypothesis-generating observational data requiring RCT confirmation.
Venous thromboembolism (VTE) is associated with increased mortality and morbidity in cancer patients, and VTE development is among the most frequent causes of death in cancer patients. In this study, we evaluated the efficacy of enoxaparin and tinzaparin on thrombosis development in 36 cancer patients. Of 36 the cases, 14 were given enoxaparin (single dose, 6000 anti-Xa/0.6 ml, s.c.), and 22 were given tinzaparin (single dose 20.000 IU/0.7 ml, s.c.). The improvement was observed following the treatment in Doppler ultrasonography and the resolution of VTE was clinically detectable. We did not observe any signs of a new thrombus development or bleeding in the patient group. We detected a longer survival time in patients with enoxaparin treatment (p<0.05). We conclude that low-molecular-weight heparins are an efficient treatment method for VTE in cancer patients.
No takes yet. Share an insight, caveat, or question.
Düzgün et al. (2021) conducted a cohort in Cancer with Venous Thromboembolism (n=36). Enoxaparin vs. Tinzaparin was evaluated on Mean survival (months) (p=<0.05). Enoxaparin treatment was associated with a significantly longer mean survival time (7.6 months) compared to tinzaparin (2.8 months) in cancer patients with venous thromboembolism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: